- Home
- MG vs PRQR Comparison
MG vs PRQR Comparison
Compare MG & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MG | PRQR |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 531.0M | 262.5M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MG | PRQR |
|---|---|---|
| Price | $18.49 | $2.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 216.8K | ★ 972.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $700,970,000.00 | N/A |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $3.59 | $13.92 |
| P/E Ratio | $64.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.35 | $1.33 |
| 52 Week High | $20.20 | $3.10 |
Technical Indicators
Market Signals| Indicator | MG | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 60.84 | 63.66 |
| Support Level | $13.37 | $1.40 |
| Resistance Level | $19.43 | $2.44 |
| Average True Range (ATR) | 1.03 | 0.15 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 61.48 | 72.39 |
Price Performance
Historical ComparisonAbout MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.